Source comparison
Kisspeptin Safe Long Term Use: Risk/Benefit Comparison
Acute Adverse Events Minimal. Injection site reactions (10–15%), headaches (<10%), no serious events No data. Longest published trial is 24 weeks intermittent dosing Short-term tolerability is well-established; chronic safety is not Receptor Desensitization Ri
This comparison does not assign a generated winner or score.
- Acute Adverse Events
- Minimal. Injection site reactions (10–15%), headaches (<10%), no serious events
- No data. Longest published trial is 24 weeks intermittent dosing
- Short-term tolerability is well-established; chronic safety is not
- Receptor Desensitization Risk
- Not observed in trials up to 24 weeks
- Unknown. Tachyphylaxis onset typically occurs after 6–18 months of chronic agonist exposure
- Theoretical risk unsupported or refuted by existing data
- Endogenous Kisspeptin Suppression
- No suppression detected during dosing windows
- Unknown. Rebound suppression after cessation would require 12+ month follow-up
- Regulatory concern that hasn't been tested
- Cardiovascular & Metabolic Effects
- No clinically significant changes in ECG, BP, glucose, lipids
- Unknown. Cardiovascular risk requires multi-year observational cohorts
- Standard monitoring captured no signals, but duration insufficient for rare event detection
- Fertility Outcomes Post-Cessation
- Normal ovulation/spermatogenesis resumed within 4–8 weeks in all trials
- Unknown. Whether years of exogenous dosing alters baseline HPG function unstudied
- Reassuring short-term recovery, but long-term axis integrity unconfirmed